Development and large-scale validation of a highly accurate SARS-COV-2 serological test using regular test strips for autonomous and affordable finger-prick sample collection, transportation, and storage
Authors:
- Renata G. F. AlvimRARenata G. F. Alvim
- Tulio M. LimaTLTulio M. Lima
- Danielle A. S. RodriguesDRDanielle A. S. Rodrigues
- Federico F. MarsiliFMFederico F. Marsili
- Vicente B. T. BozzaVBVicente B. T. Bozza
- Luiza M. HigaLHLuiza M. Higa
- Fabio L. MonteiroFMFabio L. Monteiro
- Daniel P. B. AbreuDADaniel P. B. Abreu
- Isabela C. LeitãoILIsabela C. Leitão
- Renato S. CarvalhoRCRenato S. Carvalho
- Rafael M. GalliezRGRafael M. Galliez
- Terezinha M. P. P. CastineirasTCTerezinha M. P. P. Castineiras
Preprint
Abstract
Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies. Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from a finger prick. We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen, we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing, and shipping. An overall cost estimate revealed that the final retail price could be in the range of one US dollar. The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance and follow-up of SARS-CoV-2 vaccination of populations regardless of geographical and socio-economic aspects. We hope the detailed guidelines for the development of an affordable and accurate anti-spike SARS-COV-2 ELISA, such as S-UFRJ described here, will stimulate governmental and non-governmental health agencies in other countries to engage in much-needed large-scale studies monitoring the spread and immunity to SARS-COV-2 infection.Keywords
All Related Versions
- Published version: Biochemical Engineering Journal, 186, 108537.
This publication has 15 references indexed in Scilit:
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- Serology assays to manage COVID-19Science, 2020
- Identification of conserved epitopes in SARS-CoV-2 spike and nucleocapsid proteinbioRxiv, 2020
- Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and sero-surveillancebioRxiv, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platformVaccine, 2019
- Dried Blood Spots for Global Health Diagnostics and Surveillance: Opportunities and ChallengesThe American Journal of Tropical Medicine and Hygiene, 2018
- Absorbance summation: A novel approach for analyzing high-throughput ELISA data in the absence of a standardPLOS ONE, 2018
- Importance of the cutoff ratio for detecting antibodies against hepatitis A virus in oral fluids by enzyme immunoassayJournal of Virological Methods, 2011
- Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysisJournal of Evaluation in Clinical Practice, 2006